Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics,

The Aspergillosis market growth is driven by factors like increase in the prevalence of Aspergillosis, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Aspergillosis market report [https://www.delveinsight.com/report-store/aspergillosis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Aspergillosis market size, share, Aspergillosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Aspergillosis market size growth forward.

Some of the key highlights from the Aspergillosis Market Insights Report:

*
As per DelveInsight analysis, the Aspergillosis market is anticipated to witness growth at a considerable CAGR

*
The Aspergillosis market is expected to grow significantly during the forecast period, driven by the introduction of new therapies like Opelconazole and others.

*
Several key pharmaceutical companies, including Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others, are developing novel products to improve the Aspergillosis treatment outlook.

*
In 2023, the Aspergillosis market in the 7MM was valued at around USD 2,606 million, with expectations to grow at a compound annual growth rate (CAGR) of approximately 11% by 2034.

*
In 2023, the US reported approximately 568 thousand cases of aspergillosis, with allergic bronchopulmonary aspergillosis (ABPA) accounting for 92% of these cases and chronic pulmonary aspergillosis (CPA) making up only 2%. Both forms are expected to see an increase in prevalence during the forecast period.

*
In 2023, the UK had a significant share of diagnosed prevalent aspergillosis cases among the EU4 and the UK, reporting around 179 thousand cases, while Spain had the lowest prevalence with nearly 67 thousand cases. This difference underscores the UK's leading position in the regional aspergillosis landscape, in contrast to Spain's much smaller case load.

*
In March 2024, the US FDA granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for treating invasive Aspergillosis and invasive mucormycosis in pediatric patients.

*
In April 2024, Pulmocide Ltd. announced positive topline results from the OPERA-S Phase II trial, which evaluated inhaled opelconazole in lung transplant patients. The trial showed that opelconazole was well tolerated, with fewer adverse events and drug-drug interactions than standard care, effectively preventing and eradicating pulmonary Aspergillus and Candida infections.

*
In January 2024, TFF Pharmaceuticals revealed that it would present Phase II trial data on Voriconazole Inhalation Powder (TFF VORI) for treating invasive pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference in Milan, Italy, highlighting advancements in the treatment of this severe fungal infection.

Strategise your business goals by understanding market dynamics @ Aspergillosis Market Landscape [https://www.delveinsight.com/report-store/aspergillosis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Aspergillosis Overview

Aspergillosis is a fungal infection caused mainly by *Aspergillus fumigatus*, typically affecting individuals with weakened immune systems or existing lung diseases like COPD or cystic fibrosis. It manifests in different forms, including allergic fungal sinusitis (an immune response causing chronic sinus inflammation), invasive aspergillosis (a life-threatening infection that can spread beyond the lungs in immunocompromised patients), and chronic pulmonary aspergillosis (a long-term lung infection often arising from prior lung damage).

Diagnosis involves a combination of clinical assessment, imaging, and lab tests. Doctors usually start with a medical history and symptom evaluation (persistent cough, fever, chest pain), followed by high-resolution CT scans to detect lung abnormalities typical of aspergillosis.

Do you know the treatment paradigms for different countries? Download our Aspergillosis Market Sample Report [https://www.delveinsight.com/report-store/aspergillosis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Aspergillosis Epidemiology Segmentation

DelveInsight's Aspergillosis market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Aspergillosis historical patient pools and forecasted Aspergillosis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Aspergillosis Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Aspergillosis Prevalence

*
Age-Specific Aspergillosis Prevalence

*
Gender-Specific Aspergillosis Prevalence

*
Diagnosed and Treatable Cases of Aspergillosis

Visit for more @ Aspergillosis Epidemiological Insights [https://www.delveinsight.com/report-store/aspergillosis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Aspergillosis Market Outlook

Aspergillosis, a serious fungal infection, is treated based on its type and severity, with common options including azoles (like voriconazole and posaconazole), echinocandins (such as caspofungin), and polyenes (like amphotericin B). Azoles are typically the first choice for treatment, targeting fungal cell membranes, while echinocandins are used for severe or drug-resistant cases. Polyenes are reserved for life-threatening infections. Newer therapies, like isavuconazole, offer improved safety and convenience compared to traditional options.

The Aspergillosis treatment market is poised for growth, driven by the introduction of therapies like PC945 and Olorofim, though their long-term success remains uncertain. In 2023, the U.S. market was valued at around USD 1,125 million, with a projected 10% CAGR. Across the EU4 and the UK, the market was about USD 866 million, with the UK leading and Spain having the smallest share. The market is expected to expand further as new therapies are introduced.

Aspergillosis Marketed Aspergillosis Drugs

*
CRESEMBA: Astellas Pharma/ Basilea Pharmaceutica International

Aspergillosis Emerging Aspergillosis Drugs

*
Olorofim (F901318): F2G

*
Opelconazole (PC945): Pulmocide

Aspergillosis Key Companies

*
Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others

For more information, visit Aspergillosis Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/aspergillosis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Aspergillosis Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Aspergillosis, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Aspergillosis epidemiology in the 7MM

*
Aspergillosis marketed and emerging therapies

*
Aspergillosis companies

*
Aspergillosis market drivers and barriers

Table of Contents:

1 Aspergillosis Market Key Comprehensive Insights

2 Aspergillosis Market Report Introduction

3 Competitive Intelligence Analysis for Aspergillosis

4 Aspergillosis Market Analysis Overview at a Glance

5 Executive Summary of Aspergillosis

6 Aspergillosis Epidemiology and Market Methodology

7 Aspergillosis Epidemiology and Patient Population

8 Aspergillosis Patient Journey

9 Aspergillosis Treatment Algorithm, Aspergillosis Current Treatment, and Medical Practices

10 Key Endpoints in Aspergillosis Clinical Trials

11 Aspergillosis Marketed Therapies

12 Aspergillosis Emerging Therapies

13 Aspergillosis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Aspergillosis

16 Aspergillosis Market Key Opinion Leaders Reviews

18 Aspergillosis Market Drivers

19 Aspergillosis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Aspergillosis Epidemiology 2034

DelveInsight's "Aspergillosis - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Aspergillosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Aspergillosis Pipeline 2024

"Aspergillosis Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Aspergillosis market. A detailed picture of the Aspergillosis pipeline landscape is provided, which includes the disease overview and Aspergillosis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aspergillosis-market-expected-to-rise-by-2034-regeneron-pulmocide-astellas-pharma-cipla-pulmatrix-f2g-cellix-bio-scynexis-tff-matinas-biopharma-amplyx-pharmaceuticals-cidara-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.